In contrast, METTL3 has also been discovered to be downregulated in CML, and it decreases NEAT1 m6A modification to impact CML viability and apoptosis (62). The gene discussed is METTL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.